



PATENT
Attorney Docket No. 223488
Client Reference No. JF-85US-C1D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hashimoto et al.

Group Art Unit: 1614

Application No. 10/615,329

Examiner: Unassigned

Filed: July 8, 2003

For:

FUSED-RING COMPOUNDS AND USE

THEREOF AS DRUGS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

In re Appln. of Hashimoto et al. Application No. 10/615,329

	of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	or the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.
Copic	es of the References
	Copies of all of the references listed on the enclosed Form 1449 are enclosed herewith.
\boxtimes	Copies of U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith. Copies of other references identified on the accompanying Form 1449 are enclosed herewith.
	Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
	A copy of the foreign search report is enclosed herewith.
	The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were

In re Appln. of Hashimoto et al. Application No. 10/615,329

furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

	U.S. APPLI	CATIONS	St	tatus (check d	one)	
	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
1.	. <u></u>		-			
2.						
3.			<u></u>			
Stater	nent under 37 CFR	1.97(e)				
	Information Discloration Discloration patent office	hereby states that each osure Statement was fixed in a counterpart fore filing of the Information	irst cited in a ign patent appl	ny commun lication not	ication from a	
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.					
Stater	nent under 37 CFR	1.704(d)				
	Information Discloration office in a counterjany individual desi	hereby states that each sure Statement was cited part application and that gnated in 37 CFR 1.56(Disclosure Statement.	d in a communi t this commun	ication from ication was	a foreign patent not received by	
Fees		·				
\square	No fee is owed by the IDS Fee of \$18	he applicant(s). 30 under 37 CFR 1.17(p)) is enclosed he	erewith.		

In re Appln. of Hashimoto et al. Application No. 10/615,329

Meth	od of Payment of Fees
	Attached is a check in the amount of \$. Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose.)
Auth	orization to Charge Additional Fees
\boxtimes	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)
Instr	uctions as to Overpayment
\square	Credit Account No. 12-1216. Refund
	Jel Ktl.h.
	John Kilyk, Jr., Reg. No. 30/63
	LEYDIG, VOIT & MAYYR, LTD. Two Prudential Plaza, Suite 4900
	180 North Stetson Avenue
	Chicago, Illinois 60601-6780
	(312) 616-5600 (telephone)

Date: April 20, 2005

CERTIFICATE OF MAILING

(312) 616-5700 (facsimile)

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: April 20, 2005

profile the second

Please type a plus sign (+) inside this box	TPE			
	1 5		Complete if Known	
Substitute for form 1449A/B/PTO	APR 2 5 2005 7	Application Number	10/615,329	
INFORMATION	ASCI OSLIBE	Filing Date	July 8, 2003	
INFORMATION STATEMENT BY	A ATTEN LOSSETT	First Named Inventor	Hashimoto et al.	
SIAIEMENIB	ARMINANI	Group Art Unit	1614	
(Use as many sheet	's as necessary)	Examiner Name	Unassigned	

Attorney Docket Number

Client Reference No.

223488 JF-85US-C1D1

				U.S. PATENT DOCUMENTS		
		U.S. Patent Doo	ument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	BQ	2003/0050320	A1	Hashimoto et al.	Mar. 13, 2003	
	BR	2004/0082635	A1	Hashimoto et al.	Apr. 29, 2004	
	BS	2004/0097438	A1	Hashimoto et al.	May 20, 2004	
	ВТ	6,770,666	B2	Hashimoto et al.	Aug. 3, 2004	
		·	ļ			
			•			
						-
			ı		1	

				FOREIGN	PATENT DOCUMENTS			
		Foreign Patent Document				Trans	slation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
			•					

	OTHER - NON PATENT LITERATURE DOCUMENTS							
Examiner	Doc. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		Trans	slation				
Initials	No. (boo	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**				

Examiner Signature	Date Considered		

Sheet

of

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).